Clinical Trials

514 enrolled

Nasopharyngeal Neoplasms

NCT06958328 2026-04-08

LAP100

356 enrolled

Pancreatic Neoplasms

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT06632327 2026-04-07

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT07000084 2026-04-07

GAIN-BCG

330 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05941741 2026-03-18

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Nasopharyngeal Carcinoma

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

266 enrolled

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Nasopharyngeal Carcinoma

NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

106 enrolled

Pancreatic cancer, adult

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

412 enrolled

Nasopharyngeal Neoplasms

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

418 enrolled

Nasopharyngeal Neoplasms

NCT04722978 2025-12-17

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

228 enrolled

Triple Negative Breast Neoplasms

NCT06908993 2025-12-17

COMET

133 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07272109 2025-12-15

PTCA199-16

210 enrolled

Pancreatic Neoplasms

NCT07088263 2025-12-11

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

192 enrolled

Breast Neoplasms

NCT06929286 2025-10-30

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

125 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT02514681 2025-09-10

PRECIOUS

226 enrolled

Breast Neoplasms

NCT07155629 2025-09-04

LEFT-PANC

381 enrolled

Pancreatic Cancer Resectable

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

200 enrolled

Fludzoparib" and Anti-angiogenic

NCT06018883 2025-08-07

PTCA199-3

100 enrolled

Classical hematology

Anemia

NCT06250972 2025-08-07

PTCA199-11

210 enrolled

Pancreatic Adenocarcinoma

NCT04574960 2025-07-20

NAUTICAL

14 enrolled

Urinary Bladder Neoplasms

NCT04865939 2025-07-17

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

132 enrolled

Urothelial Cancer of Renal Pelvis

NCT04907370 2025-07-16

DIAMOND

532 enrolled

Nasopharyngeal Carcinoma

NCT07062263 2025-07-14

TAB-2

220 enrolled

Biliary Tract Neoplasms

NCT06228079 2025-07-04

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

176 enrolled

Nasopharyngeal Carcinoma

NCT06897644 2025-05-25

PANThEON

340 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT06749899 2025-05-22

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

580 enrolled

Nasopharyngeal Neoplasms

NCT03750669 2025-05-13

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

324 enrolled

Pancreatic Neoplasms

NCT05342194 2025-04-23

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

480 enrolled

Cholangiocarcinoma

NCT05615818 2025-04-23

SAFIR-ABC10

800 enrolled

Biliary Tract Neoplasms

NCT04229004 2025-04-06

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

502 enrolled

Pancreatic Neoplasms

NCT02170090 2025-03-30

ACTICCA-1

789 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma

NCT00446225 2025-03-05

EURTAC

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06170489 2025-02-28

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

185 enrolled

Lymphoid

Hodgkin Disease

NCT06364904 2025-02-21

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

210 enrolled

Urinary Bladder Neoplasms

NCT05587374 2025-01-23

GEMSTONE

490 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT03840421 2025-01-13

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

468 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT00478699 2024-12-12

GECP-SCAT

500 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT02460887 2024-12-03

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

236 enrolled

Nasopharyngeal Carcinoma

NCT03673072 2024-11-12

GAIN

68 enrolled

Biliary Tract Neoplasms

NCT03598270 2024-08-30

ANITA

417 enrolled

Gynecologic

Ovarian Neoplasms

NCT05979961 2024-08-06

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

454 enrolled

Nasopharyngeal Carcinoma

NCT05764044 2024-07-30

AddChemo

365 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03017326 2024-05-13

PHITT

450 enrolled

Carcinoma, Hepatocellular, Hepatoblastoma

NCT04557020 2024-05-01

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Phase 3 Unknown

200 enrolled

Nasopharyngeal Carcinoma

NCT01827553 2024-04-11

CONKO-007

830 enrolled

Pancreatic Neoplasms

NCT02395016 2024-04-04

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

90 enrolled 18 charts

Pancreatic Neoplasms

NCT04674956 2024-04-02

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Phase 3 Unknown

401 enrolled

Pancreatic Neoplasms

NCT06327932 2024-03-25

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

320 enrolled